1 Table of Contents 1 Table of Contents 5 1.1 List of Tables 8 1.2 List of Figures 8 2 Introduction 10 2.1 Disease Introduction 10 2.2 Epidemiology 11 2.3 Symptoms 12 2.4 Etiology and Pathophysiology 14 2.5 Diagnosis 16 2.6 Disease Stages 19 2.7 Prognosis 20 2.8 Treatment Options 21 2.8.1 Treatment Algorithm 21 2.8.2 Pharmacological Treatments 23 2.8.3 Non-pharmacological Treatments 25 3 Marketed Products 26 3.1 Overview 26 3.2 Acetylcholinesterase Inhibitors 26 3.2.1 Aricept (donepezil) - Eisai 26 3.2.2 Exelon (rivastigmine) - Novartis 27 3.2.3 Razadyne (galantamine) - Janssen 27 3.2.4 Cognex (tacrine) - Shionogi 28 3.3 NMDA Receptor Antagonists 28 3.3.1 Namenda/Ebixa/Axura/Abixa (Memantine), Merz/Lundbeck/Forest/Daiichi Sankyo 28 3.4 AChEI and NMDA Receptor Antagonists 29 3.4.1 Namzaric (memantine ER + donepezil), Actavis and Adamas 29 3.5 Heat Map - Marketed Products Overview 29 4 Pipeline Analysis 31 4.1 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 31 4.2 Pipeline Analysis by Mechanism of Action 33 4.3 Promising Pipeline Candidates 36 4.3.1 MK-8931- Merck 36 4.3.2 LMTX (methylthioninium chloride) - TauRX Therapeutics 37 4.3.3 Gantenerumab (RG-1540) - Roche 39 4.3.4 AZD3293 - AstraZeneca 40 4.3.5 AB1010 (masitinib) - AB Science 41 4.3.6 BIIB037 - Biogen 42 4.3.7 TTP488 - vTv Therapeutics 42 4.3.8 EVP-6124 - FORUM Pharmaceuticals 43 4.3.9 Lu AE58054 - Lundbeck 44 4.3.10 Sodium Oligomannurarate 45 4.4 Heat Map for Pipeline Products 45 5 Clinical Trial Analysis 47 5.1 Failure Rate 47 5.1.1 Overall Failure Rate 47 5.1.2 Failure Rate by Phase and Molecular Target 47 5.2 Clinical Trial Size 48 5.2.1 Patient Enrollment per Product by Stage of Development by Molecule Type and Molecular Target 48 5.2.2 Patient Enrollment per Trial by Stage of Development by Molecule Type and Molecular Target 50 5.3 Clinical Trial Duration 52 5.3.1 Trial Duration by Stage of Development and Molecule Type 52 5.3.2 Trial Duration by Stage of Development and Molecular Target 53 5.4 Summary of Clinical Trial Metrics 55 6 Multi-Scenario Forecast 56 6.1 Geographical Markets 56 6.2 Asia-Pacific Market 56 6.3 India 60 6.3.1 Treatment Usage Patterns 60 6.3.2 Annual Cost of Therapy 62 6.3.3 Market Size 63 6.4 China 65 6.4.1 Treatment Usage Patterns 65 6.4.2 Annual Cost of Therapy 67 6.4.3 Market Size 68 6.5 Australia 70 6.5.1 Treatment Usage Patterns 70 6.5.2 Annual Cost of Therapy 72 6.5.3 Market Size 74 6.6 Japan 75 6.6.1 Treatment Usage Patterns 75 6.6.2 Annual Cost of Therapy 77 6.6.3 Market Size 78 7 Drivers and Barriers 81 7.1 Drivers 81 7.1.1 Rising Prevalence 81 7.1.2 Increasing Healthcare Reforms for Elderly Population 81 7.1.3 Increasing Health Insurance Coverage for Aged Population 81 7.1.4 Increasing Public and Policy-Maker Awareness 82 7.1.5 Greater Focus on Prodromal and Presymptomatic AD 82 7.2 Barriers 82 7.2.1 High Rate of Clinical Trial Failure 82 7.2.2 Impending Patent Cliffs and Generic Erosion 82 7.2.3 Drug Testing in Patients with Established AD and Advanced Neurodegeneration 83 7.2.4 Low Diagnosis and Treatment Rate 83 7.2.5 Additional Competition from Traditional Medicines 83 8 Deals and Strategic Consolidations 84 8.1 Licensing Deals 84 8.1.1 Deals by Region and Value 84 8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 85 8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 85 8.1.4 Key Licensing Deals 88 8.2 Co-development Deals 90 8.2.1 Deals by Region and Value 90 8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 90 8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 91 8.2.4 Key Co-development Deals 94 9 Appendix 96 9.1 All Pipeline Drugs by Stage of Development 96 9.1.1 Discovery 96 9.1.2 Preclinical 104 9.1.3 Phase I 122 9.1.4 Phase II 125 9.1.5 Phase III 128 9.2 Market Forecasts to 2021 129 9.2.1 Asia-Pacific 129 9.2.2 India 130 9.2.3 China 131 9.2.4 Australia 133 9.2.5 Japan 134 9.3 Bibliography 137 9.4 Abbreviations 146 9.5 Research Methodology 147 9.5.1 Secondary Research 148 9.5.2 Marketed Product Profiles 148 9.5.3 Late-Stage Pipeline Candidates 148 9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 149 9.5.5 Product Competitiveness Framework 149 9.5.6 Pipeline Analysis 149 9.5.7 Forecasting Model 150 9.5.8 Deals Data Analysis 151 9.6 Contact Us 151 9.7 Disclaimer 151

1.1 List of Tables Table 1: AD Market, Symptoms of AD at Different Stages of Disease 13 Table 2: AD Market, Symptoms of Mid Cognitive Impairment 13 Table 3: AD Market, Mini Mental State Exam 17 Table 4: AD Market, Alzheimer’s Disease Assessment Scale Cognitive Subscale 18 Table 5: AD Market, Mild Cognitive Impairment Diagnosis Guidelines 19 Table 6: AD Market, Global Deterioration Scale for AD 20 Table 7: AD Market, Management of AD Symptoms 23 Table 8: AD Market, Global, Pipeline Products, Discovery, 2016 96 Table 9: AD Market, Global, Pipeline Products, Preclinical, 2016 104 Table 10: AD Market, Global, Pipeline Products, Phase I, 2016 122 Table 11: AD Market, Global, Pipeline Products, Phase II, 2016 125 Table 12: AD Market, Global, Pipeline Products, Phase III, 2016 128 Table 13: MCI Market, Asia-Pacific, Market Forecast, 2014-2021 129 Table 14: AD Market, Asia-Pacific, Market Forecast, 2014-2021 129 Table 15: AD and MCI Combined Market, Asia-Pacific, Market Forecast, 2014-2021 130 Table 16: MCI Market, India, Market Forecast, 2014-2021 130 Table 17: AD Market, India, Market Forecast, 2014-2021 130 Table 18: AD and MCI Combined Market, India, Market Forecast, 2014-2021 131 Table 19: MCI Market, China, Market Forecast, 2014-2021 131 Table 20: AD Market, China, Market Forecast, 2014-2021 132 Table 21: AD and MCI Combined Market, China, Market Forecast, 2014-2021 132 Table 22: MCI Market, Australia, Market Forecast, 2014-2021 133 Table 23: AD Market, Australia, Market Forecast, 2014-2021 133 Table 24: AD and MCI Combined Market, Australia, Market Forecast, 2014-2021 133 Table 25: MCI Market, Japan, Market Forecast, 2014-2021 134 Table 26: AD Market, Japan, Market Forecast, 2014-2021 135 Table 27: MCI and AD Combined Market, Japan, Market Forecast, 2014-2021 136 1.2 List of Figures Figure 1: AD Market, Treatment Algorithm of AD 22 Figure 2: AD Market, Heat Map for Marketed Products 30 Figure 3: AD Market, Overall Pipeline 32 Figure 4: AD Market, Pipeline by Mechanism of Action (%) 35 Figure 5: AD Market, Asia-Pacific, Verubecestat Market Forecast ($m), 2020-2021 37 Figure 6: AD Market, Asia-Pacific, LMTX Market Forecast ($m), 2018-2021 38 Figure 7: AD Market, Asia-Pacific, Gantenerumab Market Forecast ($m), 2020-2021 40 Figure 8: AD Market, Heat Map for Pipeline Products 46 Figure 9: AD Market, Clinical Trial Failure Rates by Phase (%) 47 Figure 10: AD Market, Clinical Trial Failure Rates by Molecular Target (%) 48 Figure 11: AD Market, Clinical Trial Size per Product by Molecule Type (participants) 49 Figure 12: AD Market, Clinical Trial Size per Product by Molecular Target (participants) 50 Figure 13: AD Market, Clinical Trial Size per Trial by Molecule Type (participants) 51 Figure 14: AD Market, Clinical Trial Size per Trial by Molecular Target (participants) 52 Figure 15: AD Market, Clinical Trial Duration by Molecule Type (months) 53 Figure 16: AD Market, Clinical Trial Duration by Molecular Target (months) 54 Figure 17: AD Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 55 Figure 18: AD Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 55 Figure 19: AD and MCI Market, Asia-Pacific, Treatment Patterns (million), 2014-2021 57 Figure 20: AD and MCI Combined Market, Asia-Pacific, Treatment Patterns (million), 2014-2021 58 Figure 21: AD and MCI Market, Asia-Pacific, Market Size ($bn), 2014-2021 59 Figure 22: AD and MCI Combined Market, Asia-Pacific, Market Size ($bn), 2014-2021 60 Figure 23: AD and MCI Market, India, Treatment Patterns (million), 2014-2021 61 Figure 24: AD and MCI Combined Market, India, Treatment Patterns (million), 2014-2021 62 Figure 25: AD and MCI Market, India, Annual Cost of Therapy ($), 2014-2021 63 Figure 26: AD and MCI Market, India, Market Size ($m), 2014-2021 64 Figure 27: AD and MCI Combined Market, India, Market Size ($m), 2014-2021 65 Figure 28: AD and MCI Market, China, Treatment Patterns (million), 2014-2021 66 Figure 29: AD and MCI Combined Market, China, Treatment Patterns (million), 2014-2021 67 Figure 30: AD and MCI Market, China, Annual Cost of Therapy ($), 2014-2021 68 Figure 31: AD and MCI Market, China, Market Size ($m), 2014-2021 69 Figure 32: AD and MCI Combined Market, China, Market Size ($m), 2014-2021 70 Figure 33: AD and MCI Market, Australia, Treatment Patterns (‘000), 2014-2021 71 Figure 34: AD and MCI Combined Market, Australia, Treatment Patterns (‘000), 2014-2021 72 Figure 35: AD and MCI Market, Australia, Annual Cost of Therapy ($), 2014-2021 73 Figure 36: AD and MCI Market, Australia, Market Size ($m), 2014-2021 74 Figure 37: AD and MCI Combined Market, Australia, Market Size ($m), 2014-2021 75 Figure 38: AD and MCI Market, Japan, Treatment Patterns (million), 2014-2021 76 Figure 39: AD and MCI Combined Market, Japan, Treatment Patterns (million), 2014-2021 77 Figure 40: AD and MCI Market, Japan, Annual Cost of Therapy ($), 2014-2021 78 Figure 41: AD and MCI Market, Japan, Market Size ($m), 2014-2021 79 Figure 42: AD and MCI Combined Market, Japan, Market Size ($bn), 2014-2021 80 Figure 43: AD Market, Licensing Deals by Value, 2006-2015 84 Figure 44: AD Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2015 85 Figure 45: AD Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2015 86 Figure 46: AD Market, Global, Licensing Deals by Molecule Type and Value, 2006-2015 87 Figure 47: AD Market, Global, Licensing Deals by Molecular Target and Aggregate Value, 2006-2015 88 Figure 48: AD Market, Global, Co-development Deals by Value, 2006-2015 90 Figure 49: AD Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2015 91 Figure 50: AD Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2015 92 Figure 51: AD Market, Global, Co-development Deals by Molecule Type and Value, 2006-2015 93 Figure 52: AD Market, Global, Licensing Deals by Molecular Target and Aggregate Value, 2006-2015 94